Researchers have identified a key enzyme – RNase H2 – that helps triple-negative breast cancer (TNBC) cells survive high levels of DNA replication stress. Because many breast cancer therapies work by causing replication stress, these results suggest RNase H2 is a promising treatment target. The study, led by Shiaw-Yih Lin, Ph.D., professor of Systems Biology, reveals that blocking RNase H2 directly damages cancer cell DNA while also activating the innate immune system to produce signals that attract T cells...